$ACT News Icahn Enterprises reports profit up 144% in

New Post Public Reply Private Reply Replies (0) Message Board

Mar 6, 2014 at 10:13 AM

$ACT News

Icahn Enterprises reports profit up 144% in 2013 10:22 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 11:12 a.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 4:45 p.m. Feb. 24, 2014 - Victor Reklaitis
U.S. stock market is starting to ride a tech M&A wave 5:31 a.m. Feb. 24, 2014 - Wallace Witkowski
Actavis continues hot streak with better-than-expected earnings 11:21 a.m. Feb. 20, 2014 - blogs.marketwatch.com
Actavis swings to loss on charges, write-downs 8:03 a.m. Feb. 20, 2014 - MarketWatch.com
Pharma megamergers bring higher profits, better returns, study says 1:59 p.m. Feb. 19, 2014 - blogs.marketwatch.com
Actavis, Forest shares continue their climb in aftermath of $25 billion deal 11:03 a.m. Feb. 19, 2014 - blogs.marketwatch.com
U.S. stocks edge up; Nasdaq gains for 8th day in a row 4:38 p.m. Feb. 18, 2014 - Anora Mahmudova
Forest Laboratories, Actavis surge on buyout deal 4:10 p.m. Feb. 18, 2014 - Ben Eisen
S&P 500, Nasdaq extend win streaks but Dow dips: stock market live blog recap 4:06 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Forest buyout may not spell the end of dealmaking for Actavis 3:00 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Pharma ETFs pop on the Actavis-Forest deal 2:07 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Investors drive up price of Actavis-Forest deal 11:14 a.m. Feb. 18, 2014 - blogs.marketwatch.com
Actavis shares jump 7.8% on Forest Lab deal 9:35 a.m. Feb. 18, 2014 - Sue Chang
U.S. stock futures trim rise; Forest Labs soars 9:14 a.m. Feb. 18, 2014 - Sara Sjolin
Actavis-Forest Labs is play on changes in health care 9:06 a.m. Feb. 18, 2014 - Dana Mattioli
Actavis confirms $25 bln Forest Labs acquistion 7:15 a.m. Feb. 18, 2014 - Sara Sjolin
Actavis shares climb 10% on deal for Forest Labs 7:12 a.m. Feb. 18, 2014 - Silvia Ascarelli
Forest Lab surges 27% premarket on Actavis deal 7:09 a.m. Feb. 18, 2014 - Silvia Ascarelli

Vansen Pharma Inc. appoints Ali Moghaddam to its Board of Advisors 8:30 a.m. Today - CNW Group
Teva Up on FDA Nod for Generic Evista - Analyst Blog 4:06 p.m. March 5, 2014 - Zacks.com
3 Stocks Pushing The Drugs Industry Downward 12:02 p.m. March 5, 2014 - TheStreet.com
Winning Stock Sectors for Tuesday, March 4 12:15 a.m. March 5, 2014 - WallStreetSectorSelector
Precious Metals, Health Care Led Mutual Funds In Feb. 5:21 p.m. March 4, 2014 - Investors Business Daily
Forest Labs Seeks Bystolic-Diovan Approval - Analyst Blog 5:20 p.m. March 4, 2014 - Zacks.com
Top Mutual Funds Add To Health Care, Leisure And Banks 5:20 p.m. March 4, 2014 - Investors Business Daily
Drugmakers Actavis, Biogen, Valeant Hold Near Highs 4:13 p.m. March 4, 2014 - Investors Business Daily
Pernix to Market Osmotica's Khedezla - Analyst Blog 5:30 p.m. March 3, 2014 - Zacks.com
Actavis Challenges Patents - Analyst Blog 4:45 p.m. March 3, 2014 - Zacks.com
Q4 Earnings Decline Y/Y at Endo, Weak Outlook - Analyst Blog 1:26 p.m. March 3, 2014 - Zacks.com
Biogen Idec Keeps Momentum Going With MS Drug Tecfidera 1:05 p.m. March 3, 2014 - Investors Business Daily
One Hardworking Bull 1:55 a.m. March 1, 2014 - Barrons.com
Actavis PLC (ACT): Today's Featured Health Care Laggard 5:01 p.m. Feb. 28, 2014 - TheStreet.com
Seattle Genetics Presents Data on Adcetris - Analyst Blog 3:17 p.m. Feb. 28, 2014 - Zacks.com
Patent Update from Mallinckrodt - Analyst Blog 5:20 p.m. Feb. 27, 2014 - Zacks.com
Valeant Beats Q4 Estimates, Talks Buyout Strategy 4:38 p.m. Feb. 27, 2014 - Investors Business Daily
Can The Uptrend Continue for Actavis (ACT)? - Tale of the Tape 9:47 a.m. Feb. 27, 2014 - Zacks.com
Enter Biosimilars: 3 Stock Picks - Analyst Blog 1:13 p.m. Feb. 26, 2014 - Zacks.com
Wider-than-Expected Loss at Pacira - Analyst Blog 12:20 p.m. Feb. 26, 2014 - Zacks.com

Actavis to Present at Barclays Global Healthcare Conference 8:00 a.m. March 4, 2014 - PR Newswire - PRF
Actavis Confirms Generic Colcrys® Patent Challenge 4:05 p.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Confirms Generic Multaq® Patent Challenge 8:00 a.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013; Non-GAAP EPS Increases 99% to $3.17 7:00 a.m. Feb. 20, 2014 - PR Newswire - PRF
Actavis to Present at Citi's 2014 Global Healthcare Conference 4:25 p.m. Feb. 19, 2014 - PR Newswire - PRF
Critical Alerts For Actavis, athenahealth, Seattle Genetics, JP Morgan Chase, and SodaStream Released By InvestorsObserver 9:31 a.m. Feb. 19, 2014 - PR Newswire - PRF
Actavis to buy Forest Labs for $25B and GT Advanced Tech acquires exclusive rights from Kyma Tech 12:31 a.m. Feb. 19, 2014 - ACCESSWIRE
Acquisition of Forest Laboratories, Inc. by Actavis plc May Not Be in Shareholders' Best Interests 9:02 p.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Cancel Q4 and FY 2013 Earnings Call Previously Scheduled for Thursday, February 20, 2014 5:13 p.m. Feb. 18, 2014 - PR Newswire - PRF
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Forest Laboratories, Inc. Stockholders 5:01 p.m. Feb. 18, 2014 - BusinessWire - BZX
Fitch Affirms Actavis at 'BBB-' on Forest Labs Acquisition; Outlook Stable 2:52 p.m. Feb. 18, 2014 - BusinessWire - BZX
FOREST SHAREHOLDERS NOTICE:Johnson & Weaver, LLP Announces Investigation of the Forest Laboratories, Inc. Proposed Acquisition by Actavis plc 9:43 a.m. Feb. 18, 2014 - BusinessWire - BZX
INVESTOR BUYOUT ALERT - Offer to Acquire Forest Laboratories - Shareholder Rights Law Firm Tripp Levy PLLC Seeks Higher Price And More Information For Shareholders 8:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Host Fourth Quarter 2013 Earnings Conference Call and Webcast 8:00 a.m. Feb. 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Treanda® Patent Challenge 8:00 a.m. Feb. 4, 2014 - PR Newswire - PRF
Actavis Presents Outlook for Continued Long-Term Growth 7:15 a.m. Jan. 31, 2014 - PR Newswire - PRF
Actavis Announces Refocused Global Business Structure to Maximize Evolution into Global Specialty Pharmaceuticals Leadership 7:00 a.m. Jan. 31, 2014 - PR Newswire - PRF
Actavis Announces Agreement with Zhejiang Chiral Medicine Chemicals Co., Ltd to Divest Actavis Foshan, China 4:05 p.m. Jan. 24, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...